Azithromycin for cystic fibrosis

European Respiratory Journal

Volumn 24, Issue 5, 2004, Pages 834-838

  Southern, K W ^a   Barker, P M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Azithromycin; Cystic fibrosis; Forced expiratory volume in one second; Randomised controlled trial; Systematic review

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; ERYTHROMYCIN; PLACEBO;

CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HUMAN; LIVER DYSFUNCTION; LUNG FUNCTION TEST; NAUSEA; OUTCOMES RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; URTICARIA; VITAL CAPACITY; WHEEZING;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 8644251326     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00084304     Document Type: Review

References (25)

1. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681-689.
2. Lewis PA. Epidemiology. In: Hodson ME, Geddes D, eds. Cystic fibrosis. Arnold, New York, 2000; pp. 13-25.
3. Jones AP, Wallis CE. Recombinant human deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2003; 3: CD001127.
4. Ryan G, Mukhopadhyay S, Singh M. Nebulised anti-pseudomonal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2003; 3: CD001021.
5. Brennan AL, Geddes DM. Bringing new treatments to the bedside in cystic fibrosis. Pediatr Pulmonol 2004; 37: 87-98.
6. Jaffe A, Bush A. Cystic fibrosis: review of the decade. Monaldi Arch Chest Dis 2001; 56: 240-247.
7. www.cochrane.org. Date last updated: February 17 2004. Date last accessed: September 6 2004.
8. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis (Cochrane Rev). In: The Cochrane Library, issue no. 3. Chichester, John Wiley and Sons Ltd, 2004.
9. Kucers A, Crowe S, Grayson ML, Hoy J. Azithromycin. In: Kucers A, Crowe S, Grayson ML, Hoy J, eds. The use of antibiotics. Butterworth-Heinemann, Oxford, 1997; pp. 653-662.
10. Lukehart SA, Godornes C, Molini BJ, et al. Macrolide resistance in Treponema pallidum in the United States and Ireland. N Engl J Med 2004; 351: 154-158.
11. Bischoff WE, Wallis ML, Tucker KB, Reboussin BA, Sherertz RJ. Staphylococcus aureus nasal carriage in a student community: prevalence, clonal relationships, and risk factors. Infect Control Hosp Epidemiol 2004; 25: 485-491.
12. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994; 49: 531-532.
13. Bush A, Rubin BK. Macrolides as biological response modifiers in cystic fibrosis and bronchiectasis. Semin Resp Crit Care Med 2003; 24: 737-747.
14. Garey KW, Alwani A, Danziger LH, Rubinstein I. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003; 123: 261-265.
15. Inamura K, Ohta N, Fukase S, Kasajima N, Aoyagi M. The effects of erythromycin on human peripheral neutrophil apoptosis. Rhinology 2000; 38: 124-129.
16. Matsuoka N, Eguchi K, Kawakami A, et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast-like cells. Clin Exp Immunol 1996; 104: 501-508.
17. Kohri K, Tamaoki J, Kondo M, Aoshiba K, Tagaya E, Nagai A. Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. Eur Respir J 2000; 15: 62-67.
18. Rubin BK, Druce H, Ramirez OE, Palmer R. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018-2023.
19. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996; 42: 186-191.
20. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57: 212-216.
21. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360: 978-984.
22. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-1756.
23. Jones AM, Martin L, Bright-Thomas RJ, et al. Inflammatory markers in cystic fibrosis patients with transmissible Pseudomonas aeruginosa. Eur Respir J 2003; 22: 503-506.
24. Cipolli M, Cazzola G, Novelli A, Cassetta MI, Falllani S, Mazzei T. Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis. Clin Drug Invest 2001; 21: 353-360.
25. Ripoll L, Reinert P, Pepin LF, Lagrange PH. Interaction of macrolides with alpha dornase during DNA hydrolysis. J Antimicrob Chemother 1996; 37: 987-991.